The impact of emerging *Plasmodium knowlesi* on accurate diagnosis by light microscopy: a systematic review and modelling analysis

John H. Huber, Margaret Elliott, Cristian Koepfli, T. Alex Perkins

Department of Biological Sciences and Eck Institute for Global Health, University of Notre Dame, Notre Dame, IN, USA

Corresponding Author: huber.j.h@wustl.edu (JHH)

Alternative Corresponding Author: taperkins@nd.edu (TAP)

Keywords: *Plasmodium knowlesi*; misdiagnosis; light microscopy; systematic review;

Summary: Co-circulation of *Plasmodium* species parasites may limit the accuracy of malaria diagnosis by light microscopy. Variation in performance of light microscopy is highly correlated with the prevalence of the parasites in the epidemiological setting.

ABSTRACT

Background

The five *Plasmodium* spp. that cause human malaria appear similar under light microscopy, which raises the possibility that misdiagnosis could routinely occur in clinical settings. Assessing the extent of misdiagnosis is of particular importance for monitoring *P. knowlesi*, which co-circulates with the other *Plasmodium* spp.

Methods

We performed a systematic review and meta-analysis of studies comparing the performance of microscopy and PCR for diagnosing malaria in settings with co-circulation of the five *Plasmodium* spp. We assessed the extent to which co-circulation of *Plasmodium* parasites affects diagnostic outcomes. We fit a Bayesian hierarchical latent class model to estimate variation in microscopy sensitivity and specificity.

Results

Mean sensitivity of microscopy was low, yet highly variable across *Plasmodium* spp., ranging from 41.7% (95% CI: 22.8 – 64.1%) for *P. falciparum* and 40.3% (22.0 – 61.5%) for *P. vivax* to 0.119% (0.0121 – 0.640%) for *P. knowlesi*, 7.57% (2.66 – 22.0%) for *P. malariae*, and 0.180% (0.00491 – 1.21%) for *P. ovale*. Observed PCR prevalence was positively correlated with estimated microscopic sensitivity and negatively correlated with estimated microscopic specificity, though the strength of the associations varied by species.

Conclusions

Our analysis suggests that co-circulation of *Plasmodium* spp. undermines the accuracy of microscopy. Sensitivity was considerably lower for *P. knowlesi*, *P. malariae*, and *P. ovale*. The negative association between specificity and PCR prevalence imply that less frequently

41 encountered species may be misdiagnosed as more frequently encountered species. Together,
42 these results suggest that the burden of *P. knowlesi*, *P. malariae*, and *P. ovale* may be
43 underappreciated in a clinical setting.

44

INTRODUCTION

Plasmodium falciparum and *Plasmodium vivax* are the predominant parasites responsible for human malaria worldwide, causing an estimated 193.9 million and 14.3 million clinical cases in 2017, respectively [1,2]. Given their contribution to the global burden of malaria, *P. falciparum* and *P. vivax* remain the primary focus of public health efforts aimed at achieving malaria elimination and eradication [3]. However, three additional *Plasmodium* species—*P. knowlesi*, *P. malariae*, and *P. ovale*—also cause clinical episodes of malaria, though their overall burden remains uncertain due in part to routine misdiagnosis in a clinical setting [4].

Diagnosis of clinical malaria is routinely performed using light microscopy (LM). In addition to challenges presented by low or submicroscopic parasite densities [5], accurate speciation of malaria parasites using LM depends upon identification of morphological features characteristic of the *Plasmodium* spp. causing the infection. However, morphological similarities across the five *Plasmodium* spp., such as the resemblance of early blood-stage *P. knowlesi* parasites to *P. falciparum* parasites and late blood-stage *P. knowlesi* parasites to *P. malariae* parasites [3,6], undermine species-level identification of *Plasmodium* infections [7].

In settings with co-circulation of the *Plasmodium* spp., routine misdiagnosis by light microscopy has consequences for clinical decision-making and malaria control. The choice of therapeutic is specific to the *Plasmodium* spp. causing the infection [8], so misdiagnosis may lead to ineffective treatment of blood-stage parasites for all *Plasmodium* spp. infections as well as ineffective or no treatment of liver-stage parasites for *P. vivax* and *P. ovale* infections. Additionally, misdiagnosis may present challenges for monitoring *Plasmodium* spp. transmission, particularly for the emerging zoonosis *P. knowlesi*. Currently, the extent of human-to-human transmission of *P. knowlesi* is unknown [3,9], and misdiagnosis could cause

transmission clusters to appear smaller than their actual size, leading to an underestimate of transmission [10].

Consequently, measuring the extent of misdiagnosis by light microscopy is of importance to public health, and past studies have directly compared the diagnostic performance of light microscopy to polymerase chain reaction (PCR) in settings with co-circulation of *Plasmodium* spp. parasites [7,11–22]. However, these studies varied in their criteria for enrollment and other study design features, as well as in the epidemiological settings in which they were conducted. This makes direct comparison of their estimates of diagnostic performance challenging.

To synthesize across these studies, we performed a systematic review and meta-analysis of the diagnostic performance of light microscopy in settings with co-circulation of all five *Plasmodium* spp. We identified studies that compared the diagnostic performance of light microscopy to PCR and fit a hierarchical Bayesian latent class model to estimate study-level and species-level sensitivities and specificities of light microscopy. Finally, to assess whether the perceived prevalences of the five species might affect diagnostic outcomes of light microscopy, we explored the relationship between the estimates of sensitivity and specificity that we obtained and the observed PCR prevalences in each study.

METHODS

Search Strategy and Selection Criteria

In this systematic review and meta-analysis, JHH searched MEDLINE and Web of Science for studies published in English before April 30th, 2020 that compared the diagnostic performance of light microscopy (LM) and polymerase chain reaction (PCR) for *Plasmodium* spp. infections. We identified studies using the following search strategy: (*Plasmodium* OR malaria) AND

knowlesi AND ((microscopy OR microscopic OR blood film OR thick film OR thin film) AND (PCR or “polymerase chain reaction”)).

Studies met the criteria for inclusion if they compared the performance of LM and PCR on clinical samples collected in areas with endemic transmission of all five *Plasmodium* spp. that naturally infect humans (i.e., *P. falciparum*, *P. vivax*, *P. knowlesi*, *P. malariae*, and *P. ovale*). Furthermore, studies were only included if they used a PCR protocol that was capable of amplifying DNA from all five *Plasmodium* spp. Prior to 2004, the public health burden of *P. knowlesi* was underappreciated [6], so restricting our search to studies published between 2004 and 2021 ensured that the diagnostic outcomes were representative of the current clinical and diagnostic landscape.

The data were extracted from each study that met the criteria for inclusion. Because the data in each study was anonymized and reported in aggregate, ethical approvals were not required according to a determination from the University of Notre Dame Institutional Review Board that this study did not constitute human subjects research.

Data Analysis

Overview

To model the diagnostic performance of LM and PCR, we constructed a Bayesian hierarchical latent class model of clinical diagnosis [23]. In this model, the probability p_{ijkl} of obtaining LM outcome $i \in \{1,0\}$ and PCR outcome $j \in \{1,0\}$ for *Plasmodium* spp. k in study l is

$$p_{ijkl} = \begin{cases} se_{LM}^{(k,l)} se_{PCR}^{(k,l)} \theta_k^{(l)} + (1 - sp_{LM}^{(k,l)}) (1 - sp_{PCR}^{(k,l)}) (1 - \theta_k^{(l)}), & i = 1, j = 1 \\ se_{LM}^{(k,l)} (1 - se_{PCR}^{(k,l)}) \theta_k^{(l)} + (1 - sp_{LM}^{(k,l)}) sp_{PCR}^{(k,l)} (1 - \theta_k^{(l)}), & i = 1, j = 0 \\ (1 - se_{LM}^{(k,l)}) se_{PCR}^{(k,l)} \theta_k^{(l)} + sp_{LM}^{(k,l)} (1 - sp_{PCR}^{(k,l)}) (1 - \theta_k^{(l)}), & i = 0, j = 0 \\ (1 - se_{LM}^{(k,l)}) (1 - se_{PCR}^{(k,l)}) \theta_k^{(l)} + sp_{LM}^{(k,l)} sp_{PCR}^{(k,l)} (1 - \theta_k^{(l)}), & i = 0, j = 1 \end{cases} \quad (1)$$

112

113 In eq. (1), $se_{LM}^{(k,l)}$ and $sp_{LM}^{(k,l)}$ are the sensitivity and specificity of LM for *Plasmodium* spp. k in
 114 study l , $se_{PCR}^{(k,l)}$ and $sp_{PCR}^{(k,l)}$ are the sensitivity and specificity of PCR for *Plasmodium* spp. k in
 115 study l , and $\theta_k^{(l)}$ is the prevalence of *Plasmodium* spp. k among participants in study l . In many
 116 cases, $\theta_k^{(l)}$ is not equivalent to community prevalence, due to characteristics of the study
 117 participants that are not representative of the surrounding community.

118 A key assumption of the latent class model is that diagnostic outcomes are conditionally
 119 independent. That is, by assuming that the sensitivity and specificity of a given diagnostic
 120 method is unique for each *Plasmodium* spp., the outcome that we observe for one parasite
 121 species using a given diagnostic method is modelled as independent of the outcomes observed
 122 for all other parasite species and diagnostic methods. This implies that the probability of a set of
 123 diagnostic outcomes observed across all five *Plasmodium* spp. is equal to the product of the
 124 probabilities of the diagnostic outcome for each *Plasmodium* spp. Nevertheless, the assumption
 125 of conditional independence still allows for interactions between *Plasmodium* spp. that arise in
 126 the context of misdiagnosis. For example, if a *P. knowlesi* infection is misdiagnosed as a *P.*
 127 *malariae* infection using LM, then the sensitivity of LM for *P. knowlesi* and the specificity of
 128 LM for *P. malariae* are penalized, because both a false-negative *P. knowlesi* diagnosis and a
 129 false-positive *P. malariae* diagnosis occurred.

130

Accounting for Differences in Study Design

Studies identified in the systematic review varied by enrollment and diagnostic criteria. Where enrollment in a study required a positive *Plasmodium* spp. diagnosis by LM or PCR, we normalized the probabilities of eq. (1), such that they were consistent with the subset of possible diagnostic outcomes that could be observed with that study design.

Because *P. knowlesi* and *P. malariae* share morphological similarities [3,6], studies may diagnose samples as “*P. knowlesi* / *P. malariae*” with LM, indicating that the microscopist identified *P. knowlesi* and/or *P. malariae* parasites in the sample but could not make a more precise mono-infection or co-infection diagnosis. To accommodate this in our model, we defined parameters $se_{LM}^{("Pk/Pm"|Pk,l)}$ and $se_{LM}^{("Pk/Pm"|Pm,l)}$ as the sensitivities of LM to diagnose samples in study l as “*P. knowlesi* / *P. malariae*”, given that the samples contained *P. knowlesi* and *P. malariae* parasites, respectively.

Inference

Using PCR as the gold standard, we fit a hierarchical latent class model of clinical diagnosis to the studies identified in our systematic review to estimate study-level and species-level variation in LM sensitivity and specificity for each *Plasmodium* spp. We fit our model in a Bayesian framework using Stan by running four independent chains of 2,000 samples, each with a warm-up period of 1,000 samples [24]. We tested for convergence with the Gelman-Rubin statistic and pooled the independent chains for a posterior distribution of 4,000 samples. Supplementary analyses were performed to evaluate the sensitivity of our posterior estimates to the inclusion of each study and to the assumption of PCR as the gold standard. See the Supporting Information for more details.

154

155 RESULTS

156 Of the 176 unique studies identified using MEDLINE and Web of Science, 12 studies met the
 157 inclusion criteria, and their data comparing LM and PCR diagnostic performance were extracted
 158 (Fig. 1). The studies enrolled febrile patients presenting in health clinics in Malaysia (n = 7),
 159 Thailand (n = 2), Indonesia (n = 1), Myanmar (n = 1), and China (n = 1). Among the 12,690 total
 160 patients enrolled across the 12 studies, the pooled percentage positive by PCR was 17% for *P.*
 161 *falciparum*, 24% for *P. vivax*, 38% for *P. knowlesi*, 1.7% for *P. malariae*, and 0.36% for *P. ovale*
 162 (Table 1). The studies varied widely in the percentage positive by PCR across *Plasmodium* spp.,
 163 encompassing a wide range of epidemiological settings and study designs (i.e., criteria for patient
 164 enrollment) in which we estimated LM diagnostic performance.

165

Figure 1. PRISMA Flow Diagram. Flow diagram of the studies identified using MEDLINE and Web of Science for the systematic review.

171 **Table 1. Reported *Plasmodium* spp. percentage positive by diagnostic method. The percentage**
 172 **of study participants positive by LM and PCR are reported for each *Plasmodium* spp. in each**
 173 **study, along with the study location, year, and total number and type of samples collected. For**
 174 ***Pk* and *Pm* LM percentage of study participants positive, * indicates that the percentage positive**
 175 **was computed using a diagnosis of “*Pk/Pm*.”**

Ref.	Location	Samples	Type	Years	<i>P. falciparum</i>		<i>P. vivax</i>		<i>P. knowlesi</i>		<i>P. malariae</i>		<i>P. ovale</i>	
					PCR	LM	PCR	LM	PCR	LM	PCR	LM	PCR	LM
[15]	Malaysia	960	LM+	2001-	26	23	51	45	28	0.0 (0)	0.42	33	0.73	0.21
				2006	(249)	(218)	(487)	(430)	(266)		(4)	(312)	(7)	(2)
[19]	Thailand	1,874	Any	2006-	41	37	64	54	0.53	0.0 (0)	1.3	0.16	0.96	0.0
			Febrile	2007	(762)	(687)	(1192)	(1021)	(10)		(24)	(3)	(18)	(0)
[16]	Malaysia	189	LM+	2008-	37	39	35	35	22	0.0 (0)	1.1	27	0.0	0.0
				2011	(70)	(74)	(66)	(67)	(42)		(2)	(51)	(0)	(0)
[11]	Malaysia	461	LM+	2009-	7.2	12	16	13	85	92*	0.87	2*	0.0	0.0
				2011	(33)	(54)	(74)	(59)	(392)	(425)	(4)	(425)	(0)	(0)
[13]	Malaysia	227	Any	2008-	42	41	41	38	16	0.0 (0)	0.88	15	0.044	0.044
			Febrile	2010	(95)	(92)	(92)	(87)	(36)		(2)	(33)	(1)	(1)
[21]	China	560	Any	2008-	28	28	51	49	0.36	0.0 (0)	1.6	0.0 (0)	2.7	0.0
			Febrile	2012	(159)	(156)	(288)	(276)	(2)		(9)		(15)	(0)
[7]	Malaysia	303	PCR+/LM+	2010-	43	47	16	16	44	42*	0.66	42*	0.0	0.0
				2011	(130)	(142)	(47)	(47)	(132)	(128)	(2)	(128)	(0)	(0)
[12]	Thailand	297	Any	2012	9.1	3.4	8.8	5.1	0.0 (0)	0.0 (0)	0.34	0.34	0.0	0.0
			Febrile		(27)	(10)	(26)	(15)			(1)	(1)	(0)	(0)
[20]	Malaysia	457	LM+	2012-	11	12	32	30	58	40	0.22	18	0.044	0.022
				2013	(51)	(54)	(144)	(138)	(267)	(185)	(1)	(81)	(2)	(1)
[17]	Myanmar	90	Any	2013-	44	43	20	19	0.0 (0)	0.0 (0)	1.1	1.1 (1)	0.0	0.0
			Febrile	2015	(40)	(39)	(18)	(17)			(1)		(0)	(0)
[18]	Indonesia		Any	2015										
			Febrile											
	Batubara	1,270			6.2	3.4	10	6.5	12	0.0 (0)	1.2	0.0 (0)	0.0	0.0
					(79)	(43)	(131)	(83)	(148)		(15)		(0)	(0)
	Langkat	544			16	9.6	16	10	5.9	0.0 (0)	1.1	0.18	0.0	0.0
					(87)	(52)	(85)	(56)	(32)		(6)	(1)	(0)	(0)
	South Nias	1,917			12	15	17	6.8	14	0.0 (0)	5.6	0.0 (0)	0.0	0.0
					(227)	(294)	(321)	(131)	(263)		(107)		(0)	(0)
[14]	Malaysia	3,541	PCR+/LM+	2015-	4.9	4.9	2.5	2.5	92	93*	1.1	93*	0.085	0.0

It is made available under a [CC-BY 4.0 International license](#).

		2017	(173)	(174)	(87)	(87)	(3255)	(3280)	(40)	(3280)	(3)	(0)
Total	12,690	17	16	24	20	38	32	1.7	34	0.36	0.032	
		(2182)	(2089)	(3058)	(2514)	(4845)	(4018)	(218)	(4316)	(46)	(4)	

176

177

After validating on 200 simulated datasets (Fig. S1), we applied our hierarchical latent class model to the data from the 12 studies identified in the systematic review. Our fitted hierarchical latent class model captured the variation in the observed data (Fig. S2) and revealed differences in LM diagnostic performance across *Plasmodium* spp. (Fig. 2). Specifically, we estimated that the species-level mean sensitivity of LM was 41.7% (95% CI: 22.8 – 64.1%) for *P. falciparum*, 40.3% (22.0 – 61.5%) for *P. vivax*, 0.119% (0.0121 – 0.640%) for *P. knowlesi*, 7.57% (2.66 – 22.0%) for *P. malariae*, and 0.180% (0.00491 – 1.21%) for *P. ovale*. Species-level mean specificity of LM was consistently high across *Plasmodium* spp. and was estimated at 98.5% (96.7 – 99.4%) for *P. falciparum*, 98.8% (97.3 – 99.5%) for *P. vivax*, 100% (99.9 – 100%) for *P. knowlesi*, 99.3% (98.0 – 99.8%) for *P. malariae*, and 100% (100 – 100%) for *P. ovale*. These results were robust to the assumption of PCR as the gold standard (Fig. S4).

Figure 2. Group-level posterior estimates of LM diagnostic performance. The group-level distributions of LM sensitivity (A, C, E, G, I) and LM specificity (B, D, F, H, I) are shown for

Plasmodium falciparum (teal; A, B), *Plasmodium vivax* (orange; C, D), *Plasmodium knowlesi* (purple; E, F), *Plasmodium malariae* (pink; G, H), and *Plasmodium ovale* (green; I, J). Thick lines are the maximum a posteriori estimates, and thin lines are 25 posterior samples.

The variance in the hierarchical distributions of LM diagnostic performance in Fig. 2 revealed the extent of variation across studies, a feature that depended upon both the diagnostic measure and the *Plasmodium* spp. considered (Fig. 3). In general, for a given *Plasmodium* spp., we estimated greater variation across studies in LM sensitivity than specificity. For example, for *P. falciparum*, we estimated that logit-transformed standard deviation of LM sensitivity was 1.61 (1.26 – 2.09), suggesting that the range of sensitivities that fell within one standard deviation of the mean was 12.5 – 78.2%. By comparison, the estimated logit-transformed standard deviation of LM specificity for *P. falciparum* was 1.48 (1.13 – 1.93), corresponding to a range of specificities within one standard deviation of the mean of 93.8 – 99.7%. Across *Plasmodium* spp., study-level estimates of LM sensitivity and specificity for *P. falciparum*, *P. vivax*, and *P. malariae* exhibited greater variation than for *P. knowlesi* and *P. ovale*.

Figure 3. Site-level posterior estimates of LM diagnostic performance. The site-level posterior estimates of (A) LM sensitivity and (B) LM specificity are shown for *P. falciparum* (teal), *P.*

vivax (orange), *P. knowlesi* (purple), *P. malariae* (pink), and *P. ovale* (green). Circles are the median posterior estimate, and the vertical segment is the 95% credible interval. The horizontal line is the posterior median of the group-level mean, and the horizontal shaded region is the corresponding 95% credible interval.

Because the estimates of LM diagnostic performance varied across the unique studies, we then assessed its relationship with observed PCR prevalence (Fig. 4). We observed strong, positive correlations between PCR prevalence and LM sensitivity for *P. falciparum* (Pearson Correlation Test: $\rho = 0.66$; $p = 0.01$) and *P. knowlesi* ($\rho = 0.83$; $p = 0.0015$) and weaker, positive correlations for *P. vivax* ($\rho = 0.40$) and *P. ovale* ($\rho = 0.012$), though the latter two were not statistically significant associations. By contrast, for *P. malariae*, there was a negative correlation between PCR prevalence and LM sensitivity, though this estimate was also not statistically significant. Across *Plasmodium* spp., increased PCR prevalence of *P. knowlesi* was associated with reduced sensitivity of LM for *P. vivax* ($\rho = -0.58$; $p = 0.029$), highlighting a possible source of misdiagnosis. Additional negative associations were observed between PCR prevalence and LM sensitivity across *P. falciparum*, *P. knowlesi*, and *P. malariae*—*Plasmodium* spp. that are commonly misdiagnosed—though these quantities were not statistically significant.

Generally, for a given *Plasmodium* spp., PCR prevalence was negatively associated with LM specificity (Fig. 4B). For *P. knowlesi*, this association was strong and statistically significant ($\rho = -0.62$; $p = 0.017$), and additional weaker, yet statistically non-significant relationships were observed for *P. falciparum*, *P. vivax*, and *P. ovale*. The opposite relationship was observed for *P. malariae*, though this quantity was not statistically significant. Across *Plasmodium* spp., increased prevalence of *P. malariae* was associated with reduced specificities of LM for *P.*

falciparum ($\rho = -0.79$; $p < 0.001$) and *P. vivax* ($\rho = -0.72$; $p = 0.0036$), and increased prevalence of *P. knowlesi* was associated with reduced specificity of LM for *P. malariae*.

Figure 4. Correlations between *Plasmodium* spp. fever prevalence and LM diagnostic performance. The correlations between *Plasmodium* spp. fever prevalence and (A) LM sensitivity and (B) LM specificity are reported. The color represents the strength of the correlation, with red colors denoting positive correlations and blue colors denoting negative correlations. ‘*’ denotes $p < 0.05$, ‘**’ denotes $p < 0.01$, and ‘***’ denotes $p < 0.001$.

DISCUSSION

In this systematic review and meta-analysis, we estimated study-level and species-level variation in the malaria diagnostic performance of light microscopy in epidemiological settings with co-circulation of the five *Plasmodium* spp. that cause human malaria. Our analysis revealed consistently low sensitivity of light microscopy to diagnose *Plasmodium* spp. infection. Sensitivity of light microscopy was estimated to be considerably lower for *P. knowlesi*, *P. malariae*, and *P. ovale* than for *P. falciparum* and *P. vivax*. This suggests that the burden of *P.*

knowlesi, *P. malariae*, and *P. ovale* in a clinical setting may be appreciably underestimated, consistent with a recent study of *P. ovale* in health clinics in Kenya [4].

Post-hoc analyses revealed relationships between the diagnostic performance of light microscopy and the epidemiological setting. In general, we noted a positive association between the PCR prevalence of a *Plasmodium* spp. and the sensitivity of light microscopy for that *Plasmodium* spp. This supports a phenomenon whereby the more a microscopist encounters samples of a *Plasmodium* spp. infection in a clinical setting, the more likely they are to accurately identify the *Plasmodium* spp. causing that infection. By contrast, increased PCR prevalence of a *Plasmodium* spp. was associated with high false-positive probabilities for that *Plasmodium* spp. This tendency to misdiagnose malaria infections as what is most commonly encountered in that clinical setting could lead to ineffective monitoring of less commonly encountered *Plasmodium* spp., such as *P. knowlesi*, *P. malariae*, and *P. ovale*.

The high probabilities of misdiagnosis estimated in this analysis could have important consequences for malaria treatment and control. Specifically, we observed an association between increased prevalence of *P. knowlesi* and reduced sensitivity of LM for *P. vivax*. This suggests that in areas with *P. knowlesi*, infections of *P. vivax* may not be correctly diagnosed and therefore may not receive radical cure therapy to clear hypnozoites and prevent relapse [25]. Additionally, increased prevalence of *P. malariae* was associated with reduced specificity of LM for *P. vivax*, indicating that many *P. malariae* infections may be misdiagnosed as *P. vivax*. This form of misdiagnosis could unnecessarily subject individuals to radical cure therapy, potentially increasing the risk of acute hemolysis among individuals deficient of the glucose-6-phosphate dehydrogenase enzyme [26].

Routine diagnosis of clinical malaria by light microscopy may prevent effective monitoring of *P. knowlesi* transmission and burden. We estimated very low sensitivity of LM to diagnose *P. knowlesi* infections, given the morphological similarities of the parasites to those of *P. falciparum* and *P. malariae* [3,6] as well as likely delays in familiarity of *P. knowlesi* among microscopists in the health systems. Sensitivity of LM was improved in settings that allowed for a “*P. knowlesi*/*P. malariae*” diagnosis, indicating that further speciation is often not possible. Although in practice *P. knowlesi* and *P. malariae* infections diagnosed by light microscopy are confirmed by PCR in many settings [11], *P. knowlesi* infections misdiagnosed as *P. falciparum*, for instance, would not be subject to confirmatory PCR. This could lead to an underestimate of *P. knowlesi* burden, affecting epidemiological assessments of *P. knowlesi* infection risk.

Our analysis is subject to a number of limitations. Our systematic review may not have identified all studies with relevant data, including those studies not indexed by MEDLINE and Web of Science. We limited our review to studies that tested for all five *Plasmodium* spp. However, studies that included subsets of the five *Plasmodium* spp. could still be informative of species-level diagnostic performance. Our latent class model assumed conditional independence of diagnosis across *Plasmodium* spp. Future extensions of this work could account for the correlation structure of LM diagnosis across the *Plasmodium* spp., due to shared morphologies of the parasites. Additionally, to address non-identifiability issues, we assumed PCR to be the gold standard. Although sensitivity analyses revealed that our species-level estimates were robust to this assumption, future work could jointly estimate the diagnostic performance of both methods, providing a more complete characterization of misdiagnosis of *Plasmodium* spp. in settings with co-circulation of multiple *Plasmodium* species.

NOTES

Author Contributions

J.H.H. and T.A.P. conceived of the study. J.H.H. developed the methodology and performed the systematic review and analyses. J.H.H. and M.E. verified the underlying data. J.H.H., M.E., C.K., and T.A.P. interpreted the results. J.H.H. and T.A.P. wrote the initial draft, and all authors provided comments on the final draft. All authors had access to the underlying data.

Disclaimer

The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report.

Financial Support

This work was supported by a Graduate Research Fellowship from the National Science Foundation to J.H.H, a Richard and Peggy Notebaert Premier Fellowship from the University of Notre Dame to J.H.H, and the National Institute of Allergy and Infectious Diseases [grant number R21-AI137891] to C.K.

Potential Conflicts of Interest

All authors have no conflicts of interest to declare.

Acknowledgments

The authors thank Parker Ladwig for helpful advice on conducting a systematic review.

Availability of Data and Materials

All code and data to reproduce the analyses can be accessed at

https://github.com/johnhhuber/malaria_misdiagnosis.git.

REFERENCES

1. Weiss DJ, Lucas TCD, Nguyen M, et al. Mapping the global prevalence, incidence, and mortality of *Plasmodium falciparum*, 2000–17: a spatial and temporal modelling study. *The Lancet* **2019**; 394:322–331.
2. Battle KE, Lucas TCD, Nguyen M, et al. Mapping the global endemicity and clinical burden of *Plasmodium vivax*, 2000–17: a spatial and temporal modelling study. *The Lancet* **2019**; 394:332–343.
3. Feachem RGA, Chen I, Akbari O, et al. Malaria eradication within a generation: ambitious, achievable, and necessary. *The Lancet* **2019**; 394:1056–1112.
4. Akala HM, Watson OJ, Mitei KK, et al. *Plasmodium* interspecies interactions during a period of increasing prevalence of *Plasmodium ovale* in symptomatic individuals seeking treatment: an observational study. *The Lancet Microbe* **2021**; 2:e141–e150.
5. Whittaker C, Slater H, Nash R, et al. Global patterns of submicroscopic *Plasmodium falciparum* malaria infection: insights from a systematic review and meta-analysis of population surveys. *The Lancet Microbe* **2021**; :S2666524721000550.
6. Singh B, Sung LK, Matusop A, et al. A large focus of naturally acquired *Plasmodium knowlesi* infections in human beings. *The Lancet* **2004**; 363:1017–1024.
7. Barber BE, William T, Grigg MJ, Yeo TW, Anstey NM. Limitations of microscopy to differentiate *Plasmodium* species in a region co-endemic for *Plasmodium falciparum*, *Plasmodium vivax* and *Plasmodium knowlesi*. *Malar J* **2013**; 12:8.
8. Guidelines for the Treatment of Malaria. 3rd ed. Geneva: World Health Organization, 2015. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK294440/>. Accessed 16 December 2020.
9. Kantele A, Jokiranta TS. Review of cases with the emerging fifth human malaria parasite, *Plasmodium knowlesi*. *Clin Infect Dis* **2011**; 52:1356–1362.
10. Blumberg S, Lloyd-Smith JO. Comparing methods for estimating R_0 from the size distribution of subcritical transmission chains. *Epidemics* **2013**; 5:131–145.

- 351 11. Barber BE, William T, Dhararaj P, et al. Epidemiology of Plasmodium knowlesi malaria in
352 north-east Sabah, Malaysia: family clusters and wide age distribution. *Malar J* **2012**;
353 11:401.
- 354 12. Baum E, Sattabongkot J, Sirichaisinthop J, et al. Common asymptomatic and
355 submicroscopic malaria infections in Western Thailand revealed in longitudinal molecular
356 and serological studies: a challenge to malaria elimination. *Malar J* **2016**; 15:333.
- 357 13. Chua KH, Lim SC, Ng CC, et al. Development of High Resolution Melting Analysis for the
358 Diagnosis of Human Malaria. *Scientific Reports* **2015**; 5:15671.
- 359 14. Cooper DJ, Rajahram GS, William T, et al. Plasmodium knowlesi Malaria in Sabah,
360 Malaysia, 2015-2017: Ongoing Increase in Incidence Despite Near-elimination of the
361 Human-only Plasmodium Species. *Clin Infect Dis* **2020**; 70:361–367.
- 362 15. Cox-Singh J, Davis TME, Lee K-S, et al. Plasmodium knowlesi malaria in humans is
363 widely distributed and potentially life threatening. *Clin Infect Dis* **2008**; 46:165–171.
- 364 16. Goh XT, Lim YAL, Vythilingam I, et al. Increased detection of Plasmodium knowlesi in
365 Sandakan division, Sabah as revealed by PlasmoNex^{TM}. *Malar J* **2013**; 12:264.
- 366 17. Han TZ, Han KT, Aye KH, Hlaing T, Thant KZ, Vythilingam I. Comparison of microscopy
367 and PCR for the detection of human Plasmodium species and Plasmodium knowlesi in
368 southern Myanmar. *Asian Pacific Journal of Tropical Biomedicine* **2017**; 7:680–685.
- 369 18. Lubis IND, Wijaya H, Lubis M, et al. Contribution of Plasmodium knowlesi to
370 Multispecies Human Malaria Infections in North Sumatera, Indonesia. *J Infect Dis* **2017**;
371 215:1148–1155.
- 372 19. Putaporntip C, Hongsriruang T, Seethamchai S, et al. Differential prevalence of
373 Plasmodium infections and cryptic Plasmodium knowlesi malaria in humans in Thailand. *J*
374 *Infect Dis* **2009**; 199:1143–1150.
- 375 20. Yusof R, Lau YL, Mahmud R, et al. High proportion of knowlesi malaria in recent malaria
376 cases in Malaysia. *Malar J* **2014**; 13:168.
- 377 21. Zhou X, Huang J-L, Njuabe MT, Li S-G, Chen J-H, Zhou X-N. A molecular survey of
378 febrile cases in malaria-endemic areas along China-Myanmar border in Yunnan province,
379 People's Republic of China. *Parasite* **2014**; 21:27.
- 380 22. Rahim MAFA, Munajat MB, Idris ZM. Malaria distribution and performance of malaria
381 diagnostic methods in Malaysia (1980-2019): a systematic review. *Malar J* **2020**; 19:395.
- 382 23. Gonçalves L, Subtil A, de Oliveira MR, do Rosário V, Lee P-W, Shaio M-F. Bayesian
383 Latent Class Models in Malaria Diagnosis. *PLoS ONE* **2012**; 7:e40633.

- 384 24. Carpenter B, Gelman A, Hoffman MD, et al. *Stan*: A Probabilistic Programming
385 Language. J Stat Soft **2017**; 76. Available at: <http://www.jstatsoft.org/v76/i01/>. Accessed
386 17 July 2021.
- 387 25. Mueller I, Galinski MR, Baird JK, et al. Key gaps in the knowledge of Plasmodium vivax, a
388 neglected human malaria parasite. The Lancet Infectious Diseases **2009**; 9:555–566.
- 389 26. Baird JK, Battle KE, Howes RE. Primaquine ineligibility in anti-relapse therapy of
390 Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6
391 polymorphisms. Malar J **2018**; 17:42, s12936-018-2190-z.

392